Physician profile
Scott Edele
NPI 1710392584
$4,013.30
in general payments reported to CMS, 2019-2025
34 companies · $1,390 in 2025
The $1,390 reported for 2025 was more than what 91% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $411 · 2020: $456 · 2021: $470 · 2022: $454 · 2023: $443 · 2024: $390 · 2025: $1,390.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,222.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,222.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $614.34 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Novo Nordisk INC | $537.52 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $485.27 | 2019-2024 | Ubrelvy, Qulipta, Synthroid |
| Boehringer Ingelheim Pharmaceuticals, INC. | $383.24 | 2019-2025 | Jardiance |
| Amgen INC. | $302.77 | 2019-2025 | Repatha, Otezla |
| Lilly USA, LLC | $261.44 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Allergan, INC. | $161.78 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $133.95 | 2023-2025 | |
| Astellas Pharma US INC | $125.94 | 2024-2025 | Veozah |
| Abbott Laboratories | $122.90 | 2022-2025 | Freestyle Libre, Freestyle Libre 3 |
| Pfizer INC. | $110.39 | 2020-2025 | |
| Exact Sciences Corporation | $107.15 | 2023-2025 | Cologuard Collection Kit |
| Amarin Pharma, INC. | $69.60 | 2019-2021 | |
| Kowa Pharmaceuticals America, INC. | $52.46 | 2019-2025 | Zoryve |
| Merck Sharp & Dohme LLC | $47.97 | 2019-2020 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $47.49 | 2022-2024 | Quviviq |
| Nestle Healthcare Nutrition INC. | $44.46 | 2022 | |
| Novartis Pharmaceuticals Corporation | $41.60 | 2022-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $41.54 | 2019 | |
| Saluda Medical Americas, INC. | $38.98 | 2025 | Evoke |
| Sanofi Pasteur INC. | $33.50 | 2020-2023 | |
| Inspire Medical Systems, INC. | $31.33 | 2025 | Inspire |
| Biohaven Pharmaceuticals, INC. | $29.20 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $23.95 | 2021 | |
| Dexcom, INC. | $23.16 | 2025 | Dexcom G6 Transmitter |
| Biohaven Pharmaceutical Holding Company LTD. | $21.11 | 2022 | |
| Genentech USA, INC. | $18.15 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $17.17 | 2022 | |
| Phadia US INC. | $15.76 | 2022 | |
| Hologic Sales and Service, LLC | $15.15 | 2019 | |
| Ibsa Pharma INC. | $15.01 | 2020 | |
| Gilead Sciences, INC. | $13.56 | 2019 | |
| Glaxosmithkline, LLC. | $13.28 | 2022 | |
| Paratek Pharmaceuticals, INC. | $12.18 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Edele listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.